Overview

Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
This concurrent, two-part study will: I) Using overnight sleep recordings, evaluate the short- and long-term sleep-promoting effects of the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication for major depressive disorder and sleep disruption. II) Investigate the psychomotor performance of depressed patients using driving simulation testing before and during treatment with mitrazapine.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Organon
Treatments:
Antidepressive Agents
Mirtazapine